of Attachment A. MMCAP Infuse Contract Product(s) - Any Product that appears on an MMCAP Infuse contract. MMCAP Infuse Contract File Updates – electronic files sent by the MMCAP Infuse Office to the Wholesaler which provide batched MMCAP Infuse Contract Product and MMCAP Infuse contract pricing information. The MMCAP Infuse Contract File Updates are usually sent to the Wholesaler on a weekly basis. The first file (titled “Update [sequential number]”) details the MMCAP Infuse contract changes that have occurred since the last weekly communication from the MMCAP Infuse Office. The second file (titled “[sequential number] Contract [8-digit date]”) is a listing of the entire MMCAP Infuse contract as of the date provided in the title. The third file (titled “[sequential number] Pending [8-digit date]”) is a listing of the MMCAP Infuse Contract Products with future effective dates.
of Attachment A. Eligible Population, of the Contract is amended to revise the contracted number of Clients from 1,518 to 1,807.
of Attachment A. 1.3 Questions and support requests relating to the IRE Services may be made by either MCI or MCI's Customers. IRE shall be solely responsible for responding to, and will use its best efforts to resolve, MCI Customer technical problems and complaints related to or arising from the IRE services provided hereunder, and in doing so shall comply with the Trouble-Handling Procedures and Response Times listed in Section 6 Attachment A.
of Attachment A. 4.3.2 CONTRACTOR shall, by the time of closure of each referral, establish a connection, defined as a family member or natural support person who CCD2721 Page 3 of 17 December 23, 2021 was identified through FFES and is committed to being a lifelong support for the identified CLIENT, for seventy percent (70%) of CLIENTS.
of Attachment A. Any attempt by LESSEE to terminate this Lease other than as provided in this Section shall be deemed a material breach of this Lease. If this Lease is terminated for any of the foregoing reasons, and a refund of Rent already paid is warranted, LESSOR shall prorate such refund to the effective date of termination, based upon the Final Appraised Value.
of Attachment A. Eligible Population, of the Contract is amended to revise the contracted number of Clients from 272 to 324.
of Attachment A. MCI's ability to procure the Leased Circuit(s) is subject to availability of such circuit(s) from an alternate access provider. If MCI fails to enter into an agreement with an alternate access provider for the Leased Circuit(s) within thirty (30) days of the Effective Date, MCI will so notify Customer and the parties' obligations under this Agreement will terminate without liability or further obligation.
of Attachment A. MMCAP Contract Product(s) - Any Product that appears on an MMCAP contract. MMCAP Contract File Updates – electronic files sent by the MMCAP Office to the Vendor which provide batched MMCAP Contract Product and MMCAP contract pricing information. The MMCAP Contract File Updates are usually sent to the Vendor on a weekly basis. The first file (titled “Update [sequential number]”) details the MMCAP contract changes that have occurred since the last weekly communication from the MMCAP Office. The second file (titled “[sequential number] Contract [8-digit date]”) is a listing of the entire MMCAP contract as of the date provided in the title. The third file (titled “[sequential number] Pending [8-digit date]”) is a listing of the MMCAP Contract Products with future effective dates.
of Attachment A. Pulmonary Disease Services Pulmonary Disease Services (PDS) is a County Public Health Services program charged with the reporting, monitoring and control of tuberculosis (TB) in Orange County. Mandated responsibilities are included in Title 17, Section 2500, et seq., of the California Code of Regulations and Section 120100, et seq. of the California Health and Safety Code. PDS performs targeted TB screening services and treatment for latent TB infection to Orange County residents who are at highest risk for progression from TB infection to active TB disease; clinical services for evaluation and treatment of individuals with active or suspected active TB disease; contact investigations; Directly Observed Therapy (DOT); Public Health Nurse TB case management services; professional and community TB education; and epidemiology and surveillance activities. County and CalOptima Responsibilities CATEGORY County/PDS CalOptima/Health Networks Administration County PDS shall administer the Tuberculosis (TB) Control Program consistent with current Centers for Disease Control and Prevention (CDC) and California Department of Public Health (CDPH) recommendations for effective TB control practice. CalOptima will assure that appropriate tuberculosis treatment, control and prevention services are provided to CalOptima Members in accordance with the most recent guidelines recommended by the Centers for Disease Control and Prevention (CDC), the American Thoracic Society (ATS), and the Infectious Diseases Society of America (IDSA). Education and Outreach Provide education and training to CalOptima staff, Health Networks and providers regarding TB control and treatment, including the County’s universal Directly Observed Therapy (DOT) policy, as well as legal mandates for TB reporting. Work with CalOptima in providing technical assistance, training and language specific resources to CalOptima health care providers to ensure appropriate evaluation and treatment of contacts, appropriate treatment for active or suspected active TB cases, and cultural competency to effectively serve TB patients. Participate with PDS in providing education and training to CalOptima staff, Health Networks and providers regarding TB control and treatment, including the County’s universal Directly Observed Therapy (DOT) policy, as well as legal mandates for TB reporting. Work with PDS in providing technical assistance, training and language specific resources to CalOptima health care providers to ensu...
of Attachment A. Seller shall notify Buyer in accordance with Article 4(i) of the disposition of each such claim. However in the event Buyer does not fulfill any or all of the requirements set forth in Article 5(d)(2) of Attachment A, Seller reserves the right to reject subject warranty claim.
